Skip to main content

Month: February 2024

Sprott Announces Year Ended 2023 Results

TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) — Sprott Inc. (NYSE/TSX: SII) (“Sprott” or the “Company”) today announced its financial results for the year ended December 31, 2023. Management commentary “In 2023, Sprott’s Assets Under Management (“AUM”) increased by $5.3 billion (23%) to $28.7 billion driven largely by strong uranium prices and inflows to our exchange listed products. Much of this growth came late in the fourth quarter and is already positively contributing to our 2024 performance,” said Whitney George, Chief Executive Officer of Sprott. “The success of our uranium strategies has been a bright spot for Sprott clients and shareholders as they have grown to account for approximately 28% of our total AUM. During the year, we also expanded our critical materials product offerings with the...

Continue reading

Whitestone REIT Acquires Garden Oaks Shopping Center

Garden Oaks Shopping CenterGarden Oaks Shopping CenterHouston market Economic Trends, Supply and Demand, and Rent Trends chartsHouston market Economic Trends, Supply and Demand, and Rent Trends chartsHOUSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE:WSR) (“Whitestone” or the “Company”) today announced the acquisition of the grocery-anchored Garden Oaks Shopping Center in Houston. The center, which contains 107,000 leasable square feet and is 96% occupied, is in the pathway of significant development, both residential and commercial, and sits on a major thoroughfare in the area. The Aldi-anchored center has a mix of 19 service and convenience-based tenants, including a top performing Planet Fitness. Nearly 30,000 vehicles per day pass by on North Shepherd Drive.Garden Oaks Shopping Center “Garden...

Continue reading

NioBay Metals closes option agreement to acquire Foothills property

MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) — NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to announce that, in accordance with the requirements of the TSX Venture Exchange and further to its news release dated February 7, 2024 (entitled “NioBay Metals signs option agreement to acquire high-potential titanium and phosphate properties”), the Company has executed an option agreement (the “Option Agreement”) to acquire an 80% undivided interest in Vior Inc.’s Foothills Project. In accordance with the Option Agreement, NioBay Metals has made the initial $40,000 cash payment and issued 1,250,000 common shares of the Company (the “Common Shares”). The Common Shares issued pursuant to the Option Agreement are subject to a four-month hold period under applicable securities laws. About NioBay Metals...

Continue reading

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance

Positive Adjusted EBITDA* for Q4 2023 more than doubles from Q3 2023 to $5 million (Net Loss of $2.8 million) leading to a significant turnaround for the full year versus 2022 Record quarterly revenue of $23.5 million and annual revenue of $81.8 million Updated Phase 1 trial investigating sudocetaxel zendusortide in advanced ovarian cancer reaches key milestone with enrollment of first six patients Guidance for 2024 set to $87-90 million in annual revenue and a positive Adjusted EBITDA in the range of $13-15 million for the full year 2024MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results...

Continue reading

Amerigo Announces 2023 Results & Quarterly Dividend

2023 net income of $3.4 million Annual EBITDA1 of $34.6 million – $17.2 million returned to shareholders2 in 2023 Quarterly dividend of Cdn$0.03 per share declared, representing an 8.6% yield3 VANCOUVER, British Columbia, Feb. 21, 2024 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF) (“Amerigo” or the “Company”) is pleased to announce financial results for the year and three months (“Q4-2023”) ended December 31, 2023. Dollar amounts in this news release are in U.S. dollars unless indicated otherwise. Amerigo’s annual financial results included net income of $3.4 million, earnings per share (“EPS”) of $0.02 and EBITDA1 of $34.6 million. In 2023, Amerigo returned $17.2 million to shareholders despite lower copper production levels due to historically significant Chilean weather events and a higher-than-normal...

Continue reading

Agrify Corporation Announces Preliminary Unaudited Financial Results for Q4 2023 and Update on Customer Project

Expects to Achieve the Lowest Record Net Loss and Cash Burn in Company History TROY, Mich., Feb. 21, 2024 (GLOBE NEWSWIRE) — Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced preliminary unaudited financial results for the fourth fiscal quarter of 2023 and updates for its Ocean Deep/Golden Lake Business Park project. Fourth Quarter 2023 OutlookNet Loss in Q4 2023 is expected to be at a historical low of $750 thousand, compared to $2.1 million net loss in Q3 2023, and $58 million loss in Q4 2022. Loss from Operations is expected to decrease by 46% to a historical low of $2.5 million, compared to $4.6 million in Q3 2023 Gross Profit is expected to increase 105% to $1.9 million, compared to $1 million in...

Continue reading

Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

Reports fourth quarter revenue of $156 million and full year revenue of $639 million Continued strength in orders with fourth quarter book-to-bill ratio of 1.03WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2023, covering the three- and twelve-month periods ended December 31, 2023. The company is also providing financial guidance for the full year 2024. Tony J. Hunt, Chief Executive Officer of Repligen said, “During the fourth quarter, we again saw order strength, driven by our Filtration and Analytics franchises and continued momentum from new modality accounts, which reflects the differentiated nature of our products in this market. We are pleased to report...

Continue reading

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

— CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain — — Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70, respectively —  — Clinical trials ongoing for in vivo gene editing product candidates, CTX310™ and CTX320™ targeting ANGPTL3 and Lp(a), respectively — — Clinical trial ongoing for CTX211™, an allogeneic, hypoimmune, gene-edited, stem cell derived product candidate for the treatment of Type 1 Diabetes (T1D) —  — Strengthened balance sheet with $280 million registered direct offering, bringing current cash position to >$2.1 billion — ZUG, Switzerland and BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating...

Continue reading

Form 8.3 – [abrdn EUROPEAN LOGISTICS INCOME PLC – 20 02 2024] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree abrdn EUROPEAN LOGISTICS INCOME PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Click, Shop, Savor: Animal Model Market Set to Soar Past USD 4.44 Billion by 2031

The global Animal Model market size is expected to reach USD 4.44 billion by 2031 and exhibit a CAGR of 7.8% in the forecast period (2024−2031), according to Skyquest’s latest research report. The increased demand for preclinical testing in pharmaceutical and biotechnology research, rising investments in drug development and toxicology studies, the growing prevalence of chronic diseases necessitating animal-based research, advancements in genetic engineering and precision medicine requiring animal models, and the expansion of research in areas like neuroscience and regenerative medicine that heavily rely on animal models is fueling the market’s growth. Westford,USA, Feb. 21, 2024 (GLOBE NEWSWIRE) — According to SkyQuest’s latest global research of the Animal Model  market, the continued development of alternative...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.